First human test of new Cancer-Fighting antibody begins
NCT ID NCT05501821
Summary
This early-stage study tested the safety and initial effectiveness of a new experimental drug called KBA1412 in adults with advanced solid tumors that have stopped responding to standard treatments. The trial tested KBA1412 given alone and in combination with an existing immunotherapy drug (pembrolizumab) to see how well patients tolerated it and if it showed any signs of fighting their cancer. It involved a small group of 16 participants to find the right dose and gather initial safety data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dutch Cancer Institute AVL
Amsterdam, 1066 CX, Netherlands
-
Erasmus Medical Center Rotterdam
Rotterdam, 3015 GD, Netherlands
-
University Hospital Antwerp
Antwerp, 2650, Belgium
-
University Hospital Ghent
Ghent, 9000, Belgium
-
University Hospital Leiden (LUMC)
Leiden, 2333 ZA, Netherlands
Conditions
Explore the condition pages connected to this study.